



Shelbourne Hotel



C
A
N
C
E
R
R
2
0
0
7

5th International Cancer Conference of St. James's Hospital

In collaboration with Regional Oncology Programme Office, Health Services Executive & Trinity College Dublin

**Merging science & medicine
to secure positive patient care**

**Shelbourne Hotel, Dublin
3rd & 4th May 2007**



cancerconference



www.conferencepartners.ie/cancer2007



TABLE OF CONTENTS

Welcome

Regional Oncology Director

NCI

Minister for Health & Children

Pre Conference Workshop

Programme

Biographies

WELCOME



Welcome to CANCER 2007, the International Cancer Conference of St James's Hospital. This year we celebrate our 5th Anniversary and have assembled a special high quality program with international renowned leaders coming together to highlight the latest developments and challenges that we face to deliver 21st Century Medicine to Cancer Patients. The theme of this year's conference is Merging Science and Medicine to Secure Positive Patient Care.

In November 2006, the Irish Government announced its Strategy for Science, Technology and Innovation (STI) with significant initiatives planned to embed research at the centre of the National Development Plan. Health was identified as a key pillar in this Research Strategy. A second important development has been the recent announcement through the 2nd National Cancer Forum of a Cancer Control Strategy, providing a road map for cancer service development and cancer research initiatives over the next 5-10 years. Our partners in Northern Ireland are also developing similar initiatives and we very much look forward to linking with them in these developments, particularly under the auspices of the Ireland Northern Ireland National Cancer Institute Cancer Consortium.

From a Cancer perspective, both the STI Strategy and the Cancer Control Plan are significant announcements, reaffirming our Government's commitment to satisfy the requirement for Ireland to embrace the latest advances in science and medicine, investing in infrastructure and people to enable Ireland to take its place at the forefront of international developments in cancer research and cancer care. As we take our first steps towards the implementation of these initiatives, clarity of vision and purpose, allied to collective "buy in" from key stake holders including clinicians, scientists, health care professionals, state and semi state bodies, cancer charities, industry, is imperative but in a way that places the patient at the centre of the process

CANCER 2007 will address these key issues in cancer strategy, cancer care and cancer research. It will identify the key priorities at a national level to allow implementation of the Cancer Control Strategy and identify how we can appropriately embed research within our health service. This showcase of national and international leaders will critically review the latest developments in cancer biology, cancer prevention, cancer screening and cancer drug therapy.

I would like to acknowledge the significant support of colleagues at St. James's Hospital, the management and board of St. James's Hospital who have supported this initiative, the Regional Oncology Programme Office, HSE who have been unstinting in their help in the delivery of this Conference and colleagues at Trinity College Dublin who have been integral to this initiative. I would like to thank the Scientific Committee who have made such an excellent programme possible. I also take this opportunity to acknowledge the generous contributions of our sponsors – in particular I would like to thank our principal sponsors The National Cancer Institute, The Health Research Board and the Irish Cancer Society for their continued support

Given the recent affirmation of the success of the Ireland Northern Ireland National Cancer Institute Cancer Consortium with the signing of a further memorandum of Understanding in Belfast in November 2006, it is extremely encouraging to see the significant presence of key members of the National Cancer Institute and the Northern Ireland Cancer community at this meeting.

Our 5th Annual International Cancer Conference provides a forum to allow meaningful discussion on how best to serve the needs of the Irish patient. St. James's Hospital is committed to Cancer Care and Cancer Research; this conference represents a significant commitment to this aspiration. I am extremely enthusiastic about the quality of the program and look forward to meeting you all in Dublin

A handwritten signature in black ink, appearing to read "Mark Lawler". The signature is fluid and cursive.

Professor Mark Lawler



REGIONAL ONCOLOGY DIRECTOR



It is my great pleasure to contribute this foreword for Cancer 2007, our 5th international cancer conference. The principal themes remain consistent since the inaugural conference, encompassing the spectrum of current topics in cancer, from strategy, structure, and delivery of services, to cancer prevention and health promotion, cancer clinical trials and the latest developments in molecular and scientific research. The line-up of distinguished national and international speakers for Cancer 2007 attests to the established status of the conference.

The success of the conference each year has been founded on the commitment and professionalism of a highly dedicated organising committee, and on the support of so many from Ireland and internationally. We are especially indebted to our friends from the National Cancer Institute in Washington, the Belfast City Hospital, the Department of Health and Social Security in Northern Ireland, and the Department of Health and Children. I would like to thank the Health Research Board and our friends in the voluntary sector from the Irish Cancer Society for their constant support.

I would like to especially acknowledge Professor Mark Lawler for his vision and commitment to establishing an international conference, and acknowledge and thank Ms. Hilary Craig, the Regional Oncology Programme Office, for her meticulous organisation and planning. I would also like to acknowledge with sincere gratitude the support for this Conference, the Cancer Executive Committee of St. James's Hospital and of current and previous senior administrators at St. James's Hospital, in particular Ian Carter, Ellis Hardiman, and John O'Brien, as well as Dr. Thomas Mitchell, Chairman of the Hospital Board.

Professor John Reynolds
Regional Director
Cancer Services
Regional Oncology Programme Office

NCI



Welcome to Cancer 2007, the International Cancer Conference of St. James's Hospital in collaboration with the Regional Oncology Programme Office, Health Services Executive, and Trinity College Dublin. Members of the National Cancer Institute are especially proud to take an active part in this 5th anniversary event.

Cancer 2007 represents the continuation of a very productive series of meetings that showcases cancer research on the island of Ireland and facilitates the interactions between researchers on the island and those from around the world. The NCI is pleased to be able to participate again this year. I am confident that those gathered in Dublin for Cancer 2007 will greatly benefit from the scientific interchange in and around the meeting. The organizers are to be congratulated for what I am sure will be another success in this wonderful series of meetings.

Dr. Joe Harford
National Cancer Institute

MINISTER FOR HEALTH & CHILDREN



'It is a very great pleasure for me to open the 5th International Cancer Conference at the Shelbourne Hotel, Dublin. I would particularly like to acknowledge Professor Mark Lawler and the organising committee for their significant efforts in organising the conference and in attracting distinguished national and international speakers in cancer control. The principal theme of the conference is merging science and medicine to secure positive patient care. Encouraging this interconnection is essential if we are to translate new knowledge and new discoveries into improved patient care and patient outcomes. The sustained pursuit of knowledge across the continuum of cancer control that is evidenced in the oncology community both on the island and internationally is very impressive. This is reflected in the breadth of expertise at the conference and in the specialised themes to be addressed.


Every area of cancer control from prevention to diagnosis, treatment, cure and care presents unique challenges. It is the scientific and research community to whom we initially look to find answers that will improve our knowledge and help us to define better interventions. The sharing of knowledge at major conferences such as this is an essential step in the transfer of knowledge to practitioners that challenges current approaches and develops improved strategies. This is the necessary pathway to achieve our common objective to prevent and cure more cancers and continue to improve the prognosis of patients who cannot yet be cured. This is the major goal of our National Cancer Control Strategy which I launched last June and which is being implemented across the cancer continuum.

The conference also reflects the successful partnership that has developed with the National Cancer Institute in the US, with a number of key note speakers from the Institute and from other prestigious institutions in the US addressing a range of key topics. Co-operation with our cancer colleagues in Northern Ireland is evidenced in the programme. Key note speakers from major cancer institutions in Europe, mainly from the United Kingdom, will add significantly to the quality of the programme and to the discussion.

I wish the conference every success and I hope that the speakers and participants alike, and especially our visitors from abroad, enjoy their stay here in Dublin.'

Mary Harney T.D.,
Minister for Health and Children





PRE CONFERENCE WORKSHOP

WEDNESDAY 2ND MAY 2007

Innovations in Cancer Research, Institute of Molecular Medicine, St. James's Hospital

9.00	REGISTRATION
9.30	Welcome & Opening of Workshop
	Session I: INFLAMMATION AND CANCER, PARTNERS IN CRIME
	Chairs: Prof John Reynolds , Professor of Surgery, St James's Hospital and Trinity College Dublin, Ireland; Dr Stephen Lane , Chairperson Medical Board, Adelaide and Meath incorporating the National Childrens' Hospital, Tallaght, Dublin, Ireland
9.40	Speakers: Prof Laurence Egan , Professor of Pharmacology, National University of Ireland, Galway, Ireland <i>"Role of the immune system in tumour development and progression."</i>
10.10	Prof Jim Johnston , Professor of Immunology, Queens University Belfast, Northern Ireland <i>"The Polycytaemia Vera JAK2 V617F transformation is enhanced by SOCS3"</i>
10.40 COFFEE AND EXHIBITION VIEWING	
	Session II THE CANCER STEM CELL, A PARADIGM SHIFT IN OUR UNDERSTANDING OF MALIGNANCY
	Chairs: Prof Frank Barry , Scientific Director, Regenerative Medicine Institute (REMEDI) NUI Galway, Ireland; Prof Cliona O Farrelly , Chairperson, Cancer Research Ireland
11.10	Speakers: Prof Malcolm Alison , Professor of Stem Cell Biology, St Barts and The London School of Medicine, London UK <i>"Introduction to Cancer Stem Cells"</i>
11.50	Prof John O Leary , Professor of Pathology, Coombe Womens Hospital and Trinity College Dublin, Ireland <i>"Cancer stemness: lessons from teratoma biology"</i>
12.20	Dr Adrian Bracken , Biotech Research and Innovation Centre, Copenhagen, Denmark <i>"Insights into the Cancer Stem Cell Hypothesis from Epigenetics and Basic Transcriptional Biology"</i>
13.00 LUNCH AND EXHIBITION VIEWING	
	Session III: MOLECULAR IMAGING AND RADIATION ONCOLOGY: NEW INSIGHTS ON CANCER AND ITS TREATMENT
	Chairs: Dr Pierre Thirion , St Lukes Hospital, Dublin, Ireland; Prof Brian Harvey , Professor of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
14.00	Speakers: Prof Kevin Prise , Head Cell and Molecular Biophysics, Gray Cancer Institute, Middlesex, UK <i>"New insights from targeted radiation studies"</i>
14.40	Prof David Hirst , Chair in Experimental Therapeutics, Queens University Belfast, <i>"Inducible and tissue-specific promoters for cancer gene therapy"</i>
15.20	Dr Jim Meaney <i>"Title to be confirmed"</i>
16.00 COFFEE	
16.30	Dr Arvind Pathak , Radiology & Radiological Science, Johns Hopkins School of Medicine, Baltimore, USA <i>"From pixel to panacea - the role of imaging in cancer"</i>
17.10	Round table discussion: Chair Dr Ken O Byrne Head of HOPE Directorate St James's Hospital, Dublin, Ireland
17.30	END OF MEETING RECEPTION

PROGRAMME

THURSDAY 3rd MAY 2007
Shelbourne Hotel

8.15 **REGISTRATION & COFFEE**

9.00 Opening of Conference 2007

Welcome from: **Dr Tom Mitchell**, Chairperson of the Board of St. James's Hospital
Mr Padraic White, Chairperson of the Board of St. Luke's Hospital

Opening Addresses: **Prof Mark Lawler**, St James's Hospital & Trinity College Dublin
Minister Mary Harney, Minister for Health & Children, Ireland
Dr Jim Kiely, Chief Medical Officer, Department of Health & Children, Ireland
Dr Michael McBride, Chief Medical Officer, Department of Health & Social Services, Northern Ireland
Dr Joe Harford, National Cancer Institute, Washington, USA

Session I: CANCER STRATEGY: PLOTTING THE WAY FORWARD

Chairs: **Mr Tony O'Brien**, Chief Executive, National Cancer Screening Service, Ireland
Mr John McCormack, Chief Executive Officer, Irish Cancer Society, Ireland

9.30 **Speakers:** **Prof Peter Sasieni**, Cancer Research UK Clinical Centre at Bartholomews and The Royal London School of Medicine and The Wolfson Institute of Preventive Medicine, London UK
"Cancer Screening, Title to be confirmed"

10.10 **Dr Martin Brown**, National Cancer Institute, Washington, USA
"Health Services Research across the Cancer Continuum."

10.45 **COFFEE AND EXHIBITION VIEWING**

Chairs: **Dr Jim Kiely** Chief Medical Officer, Department of Health and Children, Ireland;
Mr Ian Carter, Chief Executive Officer, St James's Hospital, Dublin, Ireland

11.10 **Speakers:** **Dr Ruth Barrington** Chief Executive Officer, Health Research Board, Ireland
"Cancer Research in Ireland in 2015 – A Funder's View"

11.50 **Mr John O'Brien**, Director, National Hospitals Office, Health Services Executive, Ireland
"Implementing the Cancer Control Strategy, challenges and opportunities"

12.30 **Round Table Discussion**

Chair: **Dr Michael McBride**, Chief Medical Officer, Department of Health and Social Services, Northern Ireland

13.00 **LUNCH AND EXHIBITION VIEWING**

Session II: CANCER DRUG DISCOVERY IN THE MOLECULAR AGE

Chairs: **Prof Anita Maguire**, University College Cork, Ireland
Dr Barry Heavey, Industrial Development Authority, Ireland

13.50 **Speakers:** **Dr David Lloyd**, School of Biochemistry and Immunology, TCD, Ireland
"Oncology exploration - panning for gold in bio-molecular space"

14.25 **Dr Douglas Auld**, National Institute of Health, USA
"Quantitative High-Throughput Screening (qHTS): a valuable approach to identify Biological Activities in Large Chemical Libraries."

15.00 **Dr Terry Rabbitts**, Director, Leeds Institute for Molecular Medicine, Leeds, UK
"Macromolecular drug development and cancer experimental therapeutics"


15.40 **COFFEE & EXHIBITION VIEWING**

Session III: CANCER PREVENTION, THE TIME IS NOW!

Chairs: **Dr Doug Weed**, National Cancer Institute, Washington, USA
Dr Harry Comber, Director, National Cancer Registry, Ireland

16.10 **Speakers:** **Dr Eva Szabo**, Chief, Lung & Upper Aerodigestive CRG, Division of Cancer Prevention, National Cancer Institute, Washington, USA
"An apple a day... will chemoprevention keep the doctor away?"

16.50 **Prof Shane Allwright**, Associate Professor of Epidemiology, Department of Public Health and Primary Care, Trinity College Dublin, Ireland
"Influence of the Smoking ban on the health of Irish bar workers"



PROGRAMME

- Session IV: MOLECULAR MEDICINE & CANCER**
- Chair:** Dr Paul Browne, Chairperson, Medical Board, St James's Hospital, Dublin, Ireland
- 17.15 **State of the Art lecture:** Dr Ken Anderson, Kraft Family Professor of Medicine, Dana Farber Cancer Institute, Boston, USA
"Oncogenomics to Target Myeloma in its Bone Marrow Microenvironment"
- 18.00 ALL IRELAND CO-OPERATIVE ONCOLOGY RESEARCH GROUP (ICORG) TRANSLATIONAL RESEARCH SYMPOSIUM AND SUBGROUP MEETING
- 20.00 CONFERENCE RECEPTION - Hosted by the Vice Provost, Trinity College Dublin
- 20.30 CONFERENCE BANQUET AND ENTERTAINMENT BY NICE TOUCH

THE CANCER STRATEGIC DEVELOPMENT AWARD

The **Cancer Strategic Development Award** which is linked to the International Cancer Conference of St James's Hospital aims to recognise an individual or group of individuals who have made a significant strategic contribution in the area of cancer care, cancer prevention, cancer research or cancer related healthcare issues on the island of Ireland. It was established in 2005 and previous recipients of the award were:

2005: Minister Micheal Martin, TD, for his role while Minister of Health and Children in promoting cancer prevention by the introduction of the Smoking Ban on 29th March 2004. The recognised success of the Smoking Ban in Ireland has prompted other European countries to consider and implement similar legislation, placing Ireland at the core of a significant international health care strategic development.

2006: Prof Edison Liu (currently Executive Director, Genome Institute of Singapore) for his role in helping to establish the Ireland Northern Ireland National Cancer Institute Consortium while Deputy Director of the National Cancer Institute. The Ireland Northern Ireland National Cancer Institute Memorandum of Understanding was signed in Stormont Castle in Belfast in 1999, leading to a series of initiatives in cancer care, cancer clinical trials, cancer education and cancer prevention which have generated significant benefit for the Cancer community on the island of Ireland

This year we are delighted to honour **Prof Peter Daly**, Consultant Oncologist at St James's Hospital and Associate Professor of Oncology at Trinity College Dublin for his significant contribution to the development of oncology services, oncology research and oncology training on the island of Ireland. He was a member of the 1st and 2nd Fora on Development of Cancer Services in Ireland. He is a founder member and was the first secretary of the Irish Society of Medical Oncology. He was a founding member of ICORG, the Irish Clinical Oncology Research Group. He served on the first committee of the NCI / Ireland / Northern Ireland Cancer Consortium and remains committed to the development of cancer services as well as training and education opportunities on the island of Ireland. He also played a pivotal role in the establishment of adult genetic cancer services in Ireland. As one of the earliest consultants in the field of cancer medicine, he has been to the forefront in developing Medical Oncology in Ireland and it is in this regard that he is the recipient of the **Third Cancer Strategic Development Award**

PROGRAMME

FRIDAY 4th MAY 2007

Shelbourne Hotel

8.15 REGISTRATION & COFFEE

Session V: CANCERS OF THE GASTROINTESTINAL TRACT

Chairs: Prof Kevin Conlon, Professor of Surgery, Adelaide and Meath incorporating the National Childrens Hospital, Tallaght, Dublin, Ireland;
Prof Elaine Kay, Beaumont Hospital and the Royal College of Surgeons, Dublin, Ireland

8.40 **Speakers:** Prof Dermot Kelleher, Professor of Medicine, St James's Hospital and Trinity College Dublin, Ireland *"Oesophageal cancer; molecular insights into the inflammation – cancer sequence"*

9.20 **Prof Phil Quirke**, Professor of Pathology, Leeds Institute of Molecular Medicine and St James's University Hospital, Leeds UK
"Modern pathology and colorectal cancer"

10.00 **Prof Marc Peeters**, University of Ghent, Belgium
"Targeted therapies show great promise against colorectal cancer"

10.40 COFFEE & EXHIBITION VIEWING

Session VI: KEY NOTE ADDRESS

Chair: Dr Joe Harford, Director of International Affairs, National Cancer Institute, Washington, USA

11.10 **Speakers:** Dr Anna Barker, Deputy Director of the National Cancer Institute (NCI) and NCI Deputy Director for Advanced Technologies and Strategic Partnerships, USA
"The NCI alliance for nanotechnology in cancer"

Session VII: THE FUTURE FOR CANCER MEDICINE

Chair: Prof Des Fitzgerald
HEALTH RESEARCH BOARD STATE OF THE ART LECTURE

11.50 **Speakers:** Prof William Kaelin, Professor of Medicine, Harvard Medical School, USA
"Intelligent Selection of Drug Targets Based on Cancer Genetics"

Session VIII: COMMUNITY & OUTREACH

Chair: Mr Peter Finnegan, Director, Dublin City Development Board, Ireland

12.30 **Speakers:** Mr John Tierney, Dublin City Manager, Dublin City Council, Ireland
"The role for local government in Cancer Healthcare "

13.00 LUNCH & EXHIBITION

Session IX: SPECIAL SYMPOSIUM: ADDRESSING CANCER WITH 21ST CENTURY SCIENCE

Chairs: Prof Patrick Cunningham, Chief Science Advisor to the Government, Ireland
Dr Ken O Byrne Head of HOPE Directorate St James's Hospital, Dublin, Ireland

14.00 **Speakers:** Professor Dennis McCance, Professor of Cancer Research and Cell Biology, Queens University Belfast, Northern Ireland.
"Human Papillomaviruses (HPV) and Cancer; the role of viral proteins in targeting epithelial differentiation"

14.40 **Dr Stephen Chanock**, Head Genomic Variation Centre, Advanced Technology Centre, National Cancer Institute, USA *"Genetic susceptibility to prostate cancer – the Devil's in the DNA"*

15.20 **Prof Peter Parker**, Head of Cancer Research UK London Research Institute Laboratory, London, UK
"Insights into targeting the PI3Kinase pathway"

16.00 COFFEE & EXHIBITION VIEWING

Session X: CANCER STRATEGIC DEVELOPMENT AWARD

Chairs: Dr John Kennedy, St James's Hospital, Dublin, Ireland

16.30 **Speakers:** Prof Peter Daly, Professor of Oncology, St James's Hospital and Trinity College Dublin
"A story of Tigers and Crabs; cancer care in a changing Ireland"

17.10 CONCLUDING REMARKS & CLOSE



BIOGRAPHIES

WEDNESDAY 2ND MAY 2007

Innovations in Cancer Research, Institute of Molecular Medicine, St. James's Hospital

CHAIRS

Prof John Reynolds

Professor John V. Reynolds is Professor of Surgery and Head of Department at Trinity College Dublin. He took up this position in July 2001. He is a specialist oesophageal and gastric surgeon and is based at St. James's Hospital. He is the regional director of cancer services in the south-west area of the Eastern Regional Health Authority. His clinical and research training involved periods at the University of Pennsylvania, Philadelphia, the Memorial Sloan-Kettering Cancer Centre in New York, and St. Mary's Hospital, London. He was consultant oesophageal surgeon and senior lecturer in St. James's University Hospital in Leeds before returning to Dublin in 1997. His research interests are in molecular understanding of Barrett's oesophagus and oesophageal cancer, the molecular prediction of response or resistance to chemotherapy and radiation therapy, obesity and cancer, and modulating the immune response following complex major surgery. Professor Reynolds has edited a book on oesophageal and gastric cancer and has published approximately 100 articles on these research themes.

Dr Stephen Lane

Consultant Respiratory Physician, Department of Respiratory Medicine, AMNCH & Peamount Hospitals (1988); Clinical Senior Lecturer in Medicine Trinity College Dublin. FRCPI, FRCP (London), PhD. Special interests - inflammatory mechanisms of glucocorticoid action in bronchial asthma, lung cancer and COPD.

Prof Frank Barry

Dr. Frank Barry received a Doctorate in Biochemistry from the National University of Ireland in 1984. He has worked at the Kennedy Institute for Rheumatology, London, the Biochemistry Department of Cork University, Biocon Biochemicals (Cork), Shriners Hospital for Children, Tampa, FL, the University of South Florida College of Medicine, Tampa, FL, Case Western Reserve University, Cleveland, OH and Osiris Therapeutics Inc., Baltimore, MD. He directed a large interdisciplinary group at Osiris Therapeutics in Baltimore focusing on the biology of stem cells and translation of this research to therapeutic applications in cartilage repair, arthritis and cardiac repair. His current research interests include basic biology and therapeutic applications of stem cells in orthopaedic, cardiovascular and neurological diseases. He has published the results of his research in leading journals, book chapters, and has made many conference and workshop contributions. Dr. Barry is involved in several international and national research collaborations in cellular therapy and has served on the board of several international societies. In 2003 Dr. Barry participated in the preparation and submission of a proposal to Science Foundation Ireland for the establishment of a Centre for Science and Engineering Technology at NUI Galway. This submission resulted in an award of €25m for the establishment of the Regenerative Medicine Institute (REMEDI) of which he is now Scientific Director. The focus of research at REMEDI is the development of new strategies for treating human disease based on stem cell and gene therapy.

Prof Cliona O'Farrelly

Professor Cliona O'Farrelly is a research immunologist based at St. Vincent's University Hospital (SVUH) where she is Director of the Research Laboratories and heads the Liver Immunology Research Group with Professor John Hegarty, Medical Director of the National Liver Transplant Unit. After completing her primary degree in Microbiology (1977) and PhD (1982) at Trinity College Dublin, she spent time as a Research Fellow at St. James Hospital, Dublin and the University of Sussex. She then taught immunology at Harvard University where she also began work on her primary research interest, comparative immunogenomics, which compares immune responses in different species and their genomic influences. Since joining SVUH in 1993 and becoming a Principle Investigator of the Conway Institute, UCD, Cliona has developed research programmes comparing regional immune systems in the human gut, liver and uterus with particular focus on their roles in malignancy and infection. A recipient of the Irish Research Scientists' Association Gold Medal, the Graves Medal and the Conway Medal, Cliona O'Farrelly is currently President of the Irish Society of Immunology and Chair of Cancer Research Ireland.

BIOGRAPHIES

Pierre Thirion

Dr Thirion qualified in medicine in 1990 (University Paris V-Rene Descartes, Paris, France), and subsequently completed his fellowship in Clinical Radiation Oncology in Paris in 1995. In 1996, he completed a Masters Degree in Radiobiology as a research fellow in the Research Unit of the Institut Curie (Paris) participating in a translational research programme on development of a predictive test for individual radio-sensitivity. Then, he held a position of Clinical Lecturer in Radiation Oncology in the Henri Mondor Hospital / University Paris XII-Medical School. After moving to Ireland in 1999, he took up a position of Clinical Senior Registrar in the Radiation Oncology department in St Luke's Hospital. Since 2002, he is working as a Senior Research Registrar in the Clinical Trials Unit in St Luke's Hospital, Dublin, and concomitantly as part-time consultant Radiation Oncologist for the Mid-Western Health Board. Dr Thirion research interests concern the optimisation of current oncology treatment and the development of new radiotherapeutic technology.

Prof Brian Harvey

Prof Harvey is Vice-president for Research and Professor of Molecular Medicine at the Royal College of Surgeons in Ireland and Beaumont Hospital Dublin. He received his PhD from University College Dublin in 1992 and his DSc from the Universite of Nice in 1991. In 2007 he was elected Member of the Royal Irish Academy while he has received the Chevalier de l'Ordre Nationaldu Merite by The President of France (2006) the Lauret Prix Servier by the Servier Institute and the Fondation France-Irlande (2005) and he was elected Member of The European Academy of Sciences and Humanities in 2000. His research interests include molecular and cellular endocrinology and physiology of Rapid Responses to Steroid Hormones (RRSH) in epithelial tissues – from receptor, signal transduction, ion transport regulation to whole tissue physiology.

Dr Kenneth O'Byrne

Dr Kenneth O'Byrne is a Consultant Medical Oncologist with a particular interest in the management of thoracic malignancies. He is clinical director of the HOPE directorate at St James's Hospital and a clinical lecturer at Trinity College, Dublin. Dr. O'Byrne qualified from University College, Dublin (UCD) in 1984, completed his higher professional training in oncology at the Churchill Hospital, Oxford in 1997 and subsequently worked as a consultant and senior lecturer in medical oncology at the University Hospitals of Leicester NHS Trust and University of Leicester until October '03 before returning to Dublin in November '03. He has a Doctorate Degree in Medicine from UCD obtained in 1998 and is a Member of the Royal College of Physicians, Ireland. He is a founder member of the British Thoracic Oncology Group (BTOG) and British Mesothelioma Interest Group (BMIG) and sits on the UK National Cancer Research Institute Lung Clinical Studies Group committee. Dr O'Byrne is an active member of the Irish Society of Medical Oncology (ISMO), Irish Clinical Oncology Research Group (ICORG), All Ireland Lung Cancer Forum (AILCF), European organisation for the research and treatment of cancer (EORTC) Lung Cancer Group, British Association for Cancer Research (BACR), American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Since returning to Dublin Dr O'Byrne has set up the Thoracic Oncology Research Group based within the Clinical Trials Unit and the Institute of Molecular Medicine on the St James's Hospital Campus with an interest in carcinogenesis, identification of novel biomarkers and novel targeted therapy in lung cancer and mesothelioma. He has published over 100 manuscripts in peer-reviewed books and journals as well as over 150 non-peer reviewed articles and meeting abstracts.


SPEAKERS

Prof Laurence Egan



"Role of the immune system in tumour development and progression."

For more than 100 years it has been recognized that chronic inflammation can predispose to the development of cancer. More recently, it has been observed that immune cells such as macrophages and lymphocytes infiltrate developing tumours, but the significance of those interactions was not well understood. Recent research has begun to provide novel insights into inter-relationships between developing tumours and the immune system. In this lecture, I will review some of these old and recent findings, and present a model that proposes important cell type-specific roles for immune cells during tumourigenesis. Current and future research into the molecular factors that regulate immune-cancer cell interactions may provide new strategies for therapeutic intervention



BIOGRAPHIES

Prof Jim Johnston

“The Polycytaemia Vera JAK2 V617F transformation is enhanced by SOCS3”

Jim Johnston received his PhD from the University of Manchester in 1990 and since 2001 has been Professor of Immunology and Head of Infection and Immunity group in the Centre for Cancer Research and Cell Biology, Queen's University Belfast. He was previously a senior scientist at DNAX research Institute in Palo Alto California and prior to that a Staff Fellow at the National Institutes of Health in Bethesda, Maryland. He has many publications exploring the mechanisms that regulate cytokine signalling pathways and their importance in the immune response and malignancy. Highlights include the discovery of JAK3, and JAK3 mutations in SCID patients and the discovery of how cytokine signalling is controlled. The current research explores intracellular signalling by immunoregulatory cytokines and mechanisms of immune inhibition and regulation of tumour development. In particular the work focuses on the family of cytokine signalling inhibitors called suppressors of Cytokine Signalling (SOCS) and explores how these proteins regulate immune evasion and the development of haematological malignancies. The group have also discovered a family of deubiquitinating enzymes (DUBs) that behave as oncogenes and control cell growth and migration by regulating Ras and Rho family GTPases.

Dr Malcom Alison

“Introduction to Cancer Stem Cells”

Malcolm Alison PhD, DSc, FRCPath (m.alison@qmul.ac.uk) is Professor of Stem Cell Biology in the Centre for Diabetes and Metabolic Medicine at Barts and The London School of Medicine He has published over 150 scientific papers and chapters, particularly concerned with adult stem cells. He is Chairman of the Council of the European Society for Cell Proliferation (ESCP), a member of the Council of the European Society for Organ Transplantation (ESOT). Editorial Board Member of 'The American Journal of Pathology' 'Cell Proliferation' 'The International Journal of Experimental Pathology' (Assistant editor), 'The Journal of Pathology' and 'Stem Cell Reviews'. Co-authored, with Nick Wright, a two volume monograph entitled The Biology of Epithelial Cell Populations, published in 1984. Co-authored a monograph entitled Understanding Cancer: from basic science to clinical practice; published by Cambridge University Press in 1997. Co-editor of the 2002 Annual Review Issue (Stem Cells) of the Journal of Pathology. Editor for an issue of Seminars in Cell & Developmental Biology [13 (6)] on 'Stem cells and Liver Regeneration'. Editor-in-Chief of a major reference book on Oncology ('The Cancer Handbook'); published in January 2002 by The Nature Publishing Group. (see www.wiley.com/go/ch2), the second edition will appear in Spring 2007.

Prof John O'Leary

“Cancer stemness: lessons from teratoma biology”

Professor O'Leary is currently the Professor of Pathology at the Trinity College in Dublin, since 2002. Prior to this he held a position as Director of Pathology at the Coombe Women's Hospital, Dublin for four years, Visiting Professor, Cornell University Medical School, USA and Lecturer in Pathology at The University of Oxford, UK. Professor O'Leary received his PhD from the University of Oxford, and MD from the National University of Ireland. He received his undergraduate degree from University College Cork. Professor O'Leary has published more than a hundred papers in International peer reviewed journals, and over a hundred abstracts, including ten invited reviews and contributed nineteen chapters in books with research interest covering Molecular Pathology, Cervical Cancer, Array Technology development, Biomarkers of disease and Prostate Cancer

BIOGRAPHIES

Adrian Bracken

"Insights into the Cancer Stem Cell Hypothesis from Epigenetics and Basic Transcriptional Biology"

Adrian Bracken graduated with a BSc in Microbiology and Chemistry from University College Dublin in 1996 and obtained his PhD from Trinity College Dublin in 2000. From 2001 to 2005, Dr. Bracken worked as a post doctoral research fellow in the laboratory of Professor Kristian Helin at The European Institute of Oncology, Milan Italy, where he became interested in the field of epigenetics and particularly Polycomb group proteins. During this period he demonstrated that the Polycomb protein EZH2 is overexpressed in cancer. From 2005 to 2007 he worked as a senior research scientist at BRIC, Copenhagen where he continued to work in the emerging field of epigenetics and made several contributions to the understanding of the role of epigenetics to stem cell biology. Dr. Bracken will return to Ireland to start his own research group in Dublin in 2007/2008. His laboratory will continue to work on the epigenetic control of important cellular decisions such as proliferation, differentiation and stem cell maintenance. A key challenge will be to use this knowledge to improve cancer diagnosis and treatment.

Prof Kevin Prise

"New insights from targeted radiation studies"

Kevin M. Prise has recently joined the Centre for Cancer Research & Cell Biology at Queen's University Belfast as Professor of Radiation Biology. He originally graduated from the University of Aberdeen with an Honours degree in Biochemistry and followed this with a PhD in Biochemistry/Cell Biology studying the mechanisms of action of the chemotherapeutic agents methotrexate and 5-fluorouracil. Since then he has done extensive studies on the mechanisms of action of ionising radiations in a range of model DNA, cell and tissue systems. He has worked at the internationally renowned Gray Cancer Institute in Northwood, Northwest London where, for the past 3 years, he has been Head of the Cell and Molecular Radiation Biology Group. His current interests are in cell signalling with particular emphasis on stress-induced DNA damage and repair signalling, cell-cell communication in response to targeted irradiation and the use of different qualities of radiation as mechanistic probes. In collaboration with his colleagues at the Gray Cancer Institute, he has developed novel approaches for targeting a range of different types of radiation to cellular and subcellular targets. These approaches have challenged the accepted models for radiation effects at the cellular and subcellular levels and may offer the possibility of new approaches and targets for therapy as well as impacting on our understanding of the risks associated with low dose exposures.

Prof David Hirst

"Inducible and tissue-specific promoters for cancer gene therapy"

David Hirst has worked in Experimental Cancer Therapeutics for the past 32 years, holding posts at Stanford University, the Gray Cancer Institute and the University of Ulster, before joining the School of Pharmacy at Queen's University Belfast in July 2004 to take up the Chair in Experimental Therapeutics. His research is in 4 main areas: cancer gene therapy, development of novel anti-angiogenic agents and enhancement of radiotherapy by incorporation of heavy atoms into tumours and mechanistic studies of novel inhibitors of poly (ADP ribose) polymerase. The gene therapy programme has focused for the past five years on development of novel vector and transcriptional targeting approaches for expression of inducible nitric oxide synthase within tumours, leading to cellular apoptosis, inhibition of angiogenesis and metastasis, and radiosensitisation through generation of nitric oxide. Preclinical optimisation of this therapy for entry into a clinical trial is currently at an advanced stage.



BIOGRAPHIES

Arvind Pathak

"From pixel to panacea the role of imaging in cancer"

Dr. Arvind P. Pathak is an Assistant Professor in the Russell H. Morgan Department of Radiology and Radiological Science and the department of Oncology at the Johns Hopkins University School of Medicine. He is also an integral member of the In Vivo Cellular and Molecular Imaging Center at Johns Hopkins University. Dr. Pathak received the B.E. degree in industrial electronics from the University of Poona, India in 1993, where he specialized in the design of microprocessor-based systems. In 2001, he received the Ph.D. degree from the joint doctoral program in Functional Imaging between the Biophysics department at the Medical College of Wisconsin, and the department of Biomedical Engineering at Marquette University, Wisconsin. His dissertation was focused on the biophysics of susceptibility-based MR contrast mechanisms and its efficacy in assessing tumor angiogenesis. He continued his research into the relationship between image contrast and tumor physiology at the Johns Hopkins University School of Medicine, first as a postdoctoral fellow in the Oncology/Molecular Imaging section of the MR Research Division in the Department of Radiology, and since 2003 as faculty, where his research is focused on the Functional and Molecular Imaging of cancer.

THURSDAY 3rd MAY 2007
Shelbourne Hotel

CHAIRS

Dr Tom Mitchell

Mr Padraic White

Padraic White is Chairman of St Lukes Hospital, Rathgar Dublin the major radiotherapy treatment centre in Ireland and is Chairman of the National Radiation Oncology Oversight Group which reports regularly to the Minister for Health Mary Harney TD on the progress of the Governments plan for radiation oncology services. He is Chairman of a number of private sector companies: Certification Europe Ltd; Arigna Fuels Ltd; Moneenatieve Wind Energy Ltd; Collins Mc Nicholas Recruitment Ltd; City Broadcasting Ltd [Q102 radio].

He is committed to the regeneration of the West Belfast and Greater Shankill area in Belfast and is chair of the Enterprise Council and of the Employment Services Board in the combined area.

He is former Managing Director of the Industrial Development Authority of Ireland and co-author with Ray Mc Sharry of the book "The Making of the Celtic Tiger – the inside story of Ireland's Boom Economy". He was the first Chairman of the successful LUAS-light rail State organization [RPA].

Dr Michael Mc Bride

Dr Michael McBride was appointed to the post of Chief Medical Officer for the Department of Health, Social Services and Public Safety in September 2006. Prior to joining the department Dr McBride had been Medical Director at the Royal Group of Hospitals from August 2002. He graduated with Distinction from Queen's University Belfast in 1986 and completed his undergraduate and postgraduate training in Northern Ireland. In 1991 he attained a Research Fellowship at St Mary's Medical School and Imperial College London, where he carried out research into new drug treatments for HIV. Dr McBride has been a Consultant in the Health Service since 1994 when he was appointed Consultant Physician in HIV medicine at the Royal Group of Hospitals and has more than 10 years health service management experience.

Dr Tony O'Brien

Tony O'Brien, Chief Executive Officer, National Cancer Screening Service. Tony O'Brien was appointed Chief Executive of the National Cancer Screening Service Board on its establishment on 1st January 2007. He was Director of BreastCheck the National Breast Screening Programme since 2002 and has led the national expansion of the Programme. He was a member of the Interim HSE Change Management Team and is currently Project Director of the National Plan for Radiation Oncology and an advisor to the HSE on the implementation of the National Cancer Control Programme. He was previously Chief Executive of both the UK and Irish Family Planning Associations.

The National Cancer Screening Service is responsible for national roll-out of Breast-Check, the establishment of a National Cervical Screening Programme and is preparing for a possible colo-rectal screening programme.

BIOGRAPHIES

Mr John McCormack

Mr John McCormack was appointed CEO of the Irish Cancer Society in October 2002. He was formerly Company Secretary and Financial Controller with the Society, is a member of the Institute of Certified Public Accountants in Ireland and holds an MBA from Dublin City University. Two of Mr McCormack's key areas of interest are men's health and palliative care. In November 2003, he was instrumental in launching the first ever Men's Cancer Action Week. This initiative is now an annual event undertaken to raise awareness among men of the steps they can take to help reduce their risk of developing common cancers and to promote the benefits of early detection for long-term survival. Mr. McCormack is also involved in lobbying for the implementation of a nationwide cervical cancer screening programme and for the implementation of the recommendations of the 2001 Report of the National Advisory Committee on Palliative Care. In addition, he led the Irish Cancer Society in hosting the 4th World Conference of Cancer Organisations in November 2004.

Dr Jim Kiely

Dr Kiely has been Chief Medical Officer of the Department of Health and Children since 1997 having previously been Deputy CMO. As CMO, Dr Kiely has been involved in a number of initiatives relating to various aspects of health policy such as Hanly Committee, was on the Steering Group which oversaw the preparation of the Health Strategy, and chaired the Reform Programme Action Project on the establishment of the Health Information and Quality Authority. 1999 saw the publication of the first Chief Medical Officer's Report on the state of the health of the population, and a number of subsequent reports have dealt with issues such as Children's Health and Better Health Through Prevention. Currently, Dr Kiely's main areas of activity are in Pandemic Influenza Planning, Vaccination Policy and Healthcare Associated Infections. At international level, Dr Kiely has represented the Department on a number of WHO, EU and Council of Europe committees. He chaired Committee A of the World Health Assembly in 2002 and was Executive President of the Euro Regional Committee in 2001. Since its establishment in 1999, Dr Kiely has been co-chair of the Ireland/NCI Cancer Consortium.

Dr Ian Carter

Mr. Carter is currently the Chief Executive Officer at St James' Hospital which is a 998 bed academic teaching hospital in Ireland. Prior to this he has held senior hospital management positions within Ireland – Deputy CEO, St. James's Hospital, General Manager, Acute Hospitals, Mid Western Health Board; England – Directory of Contracts and Business Administration, 1st Wave Hospital Trust – Regional Surgical Specialties Manager; Saudi Arabia – Assistant Hospital Manager. For the last 7 years, Mr. Carter has also held the post of Associate Lecturer, National College of Ireland, with specific areas of interest in Organisational Behaviour Management Theory.

Prof Anita Maguire

Professor Maguire is Professor of Pharmaceutical Chemistry at University College Cork, and Director of the Analytical & Biological Chemistry Research Facility at University College Cork, She directs the Organic and Pharmaceutical Synthesis Research Team at UCC, currently consisting of 19 full-time researchers. Her research interests in Synthetic Organic Chemistry and Pharmaceutical Chemistry include development of new synthetic methodology, asymmetric synthesis including biocatalysis, and the design and synthesis of bioactive compounds with pharmaceutical applications. She interacts extensively with the pharmaceutical industry both within Ireland and internationally. She is currently a member of the Irish Research Council for Science, Engineering and Technology (IRCSET), the Advisory Council for Science, Technology and Innovation (ACSTI), and the Royal Irish Academy Chemical and Physical Sciences Committee, and the Board of NIBRT. She undertook undergraduate and postgraduate studies at UCC (B.Sc. 1985, Ph.D. 1989) and then worked as a Postdoctoral Associate at the Facultes Universitaires, Namur, Belgium and a Postdoctoral Fellow at the University of Exeter before returning to the Department of Chemistry in UCC in 1991. She was elected to the Governing Body of University College Cork in December 2003.



BIOGRAPHIES

Barry Heavey

Graduated with a BSc in Biotechnology from NUI Galway. Completed a PhD at the Institute of Molecular Pathology, Vienna in the field of haematopoietic stem cell biology. Academic career included research at Cornell Medical School, Basel Institute of Immunology and a five year BBSRC postdoctoral fellowship at University of Edinburgh working with Professor Austin Smith in embryonic stem cell research. Industry experience includes scientific researcher positions with Glaxo Wellcome (London) and Boehringer Ingelheim (Vienna) and business development executive position with Stem Cell Sciences Ltd. (Edinburgh). Was directly responsible for drawing up prospectus for the listing of Stem Cell Sciences Ltd on the Alternative Investment Market (AIM) in June 2005. MBA with Distinction was awarded from the University of Edinburgh Management School in May 2005. Joined the Irish Industrial Development Agency (IDA Ireland) in Feb 2006 as a technology analyst for the life science sector. Current role focuses on encouraging R&D collaboration between the Biopharma/medtech industry and academic/clinical researchers. In 2006 IDA supported a 5 year, €14M translational research collaboration on Inflammatory Bowel Disease between GSK and academic/clinical researchers in the Alimentary Pharmabiotics Centre in Cork.

Dr Doug Weed

Douglas L. Weed, M.D., M.P.H., Ph.D. is Vice President for Epidemiology and Biostatistics at THE WEINBERG GROUP INC. an international scientific and regulatory consulting firm in Washington DC. He is a physician-epidemiologist with twenty-five years of experience at the National Cancer Institute (NCI). At NCI he served as the Chief of the Office of Preventive Oncology and directed the Cancer Prevention Fellowship Program and the International Summer Curriculum in Cancer Prevention. Dr. Weed is an internationally recognized scholar and educator. His expertise includes: weight of evidence analysis, research synthesis, and general causation with applications to risk assessment and toxic tort litigation. He has special expertise in research ethics and bioethics, as well as systematic reviews, the precautionary principle, and scientific judgment. He recently chaired the Prevention Working Group of the All-Ireland/NCI Cancer Consortium. He has co-chaired a National Academy of Science committee on the Daubert decision. Dr. Weed holds an academic appointment at the Johns Hopkins University School of Public Health, and has been a Senior Fellow at the Kennedy Institute of Ethics at Georgetown University and a Visiting Scholar at the Federal Judicial Center. He is Reviews Editor of the Journal of the National Cancer Institute and Associate Editor of the American Journal of Epidemiology. Dr. Weed holds degrees from Ohio State University in Engineering and Internal Medicine (BSc and MD), and the University of North Carolina in Epidemiology (MPH and PhD).

Dr Harry Comber

Dr Paul Browne

Paul Browne is a Consultant Haematologist at St. James's Hospital and a Lecturer at the Department of Haematology, School of Medicine, Trinity College Dublin. He received his medical degree at the University of Dublin, Trinity College in June 1986. He undertook a fellowship in haematology at the University of Minnesota Medical School, Minneapolis, United States from 1992 to 1995. His research interest includes the molecular pathology of multiple myeloma. He is currently the chairman of the St James's Hospital Medical Board and vice chair of the Irish Clinical Oncology Research Group.

SPEAKERS

BIOGRAPHIES

Prof Peter Sasieni

"Cancer Screening, Title to be confirmed"

Peter Sasieni is Professor of Biostatistics and Cancer Epidemiology at Queen Mary, University of London. After graduating in mathematics from Cambridge University, he went to the University of Washington in Seattle to do a masters degree in biostatistics. He stayed for 5 years leaving with a PhD. In 1989 he joined Jack Cuzick's group at the Imperial Cancer Research Fund. He continued to research methodological issues related to the analysis of clinical trials, but also started epidemiological research. Over the years he has specialised in cancer screening and chemoprevention research with particular interest in cervix cancer. He still works with Jack Cuzick, but they are now based in a Cancer Research UK funded department at Bart's and The London Queen Mary's School of Medicine and Dentistry. In 2006 Professor Sasieni was awarded a Cancer Research UK grant to set-up a clinical trials unit specialising in cancer screening and prevention. He is the director of the new unit.

Dr Martin Brown

"Health Services Research across the Cancer Continuum."

Martin L. Brown, Ph.D. has been the Chief of NCI's Health Services and Economics Branch since October 1999. Dr. Brown received his Ph.D. in Natural Resource Economics, from the University of California, Berkeley, in 1981. He joined the NCI in 1988 as a Health Economist, after serving as Associate Professor in the Economics Department at Howard University. Since coming to NCI his research has focused on the economic burden of cancer to individuals and society, the acquisition and analysis of economic data on cancer prevention and control, evaluation and development of methodology and analytical tools for modeling and estimating the cost-effectiveness of specific cancer prevention and control interventions, programs and policies, the relationship of socioeconomic status, community structure and health system organization to access to cancer control services in the context of the changing system of healthcare delivery organization and financing. He has published over 80 articles, reports and book chapters in these research areas. Dr. Brown is economics editor of the Journal of the National Cancer Institute, has served as a reviewer for many journals and has served on peer-review committees for the National Cancer Institute of Canada and the California Cancer Research Program. Dr. Brown serves as NCI Program Director for the Cancer Research Network, a national consortium of research organizations, affiliated with integrated healthcare delivery systems, that conduct population-based research on cancer epidemiology, prevention and control. Dr. Brown received the NIH Merit Award in 1997, 2001, 2002, 2003 and 2004 and the NIH Director's Award in 2002.

Dr Ruth Barrington

"Cancer Research in Ireland in 2015 – A Funder's View"

Dr Ruth Barrington has been the Chief Executive of the Health Research Board (HRB) since 1998. She steps down from the post at the end of May 2007. The HRB is the chief funding agency for competitive, peer reviewed health research in Ireland and is a major provider of research and information services to the health system. Dr Barrington is a graduate of University College Dublin, the College of Europe in Belgium and was awarded a Ph.D from the London School of Economics. She is the author of Health, Medicine and Politics in Ireland, 1900-1970 and other publications on health and research policy. She is a member of the Board of the Health Information and Quality Authority. She represented the HRB on the Ireland/Northern Ireland/National Cancer Institute Cancer Consortium since its foundation in 1999. She is a member of the Advisory Committee to the Health Service Executive on the National Cancer Control Programme. She was an Irish representative to the European Strategy Forum on Research Infrastructure (ESFRI) and chaired the Working Group that prepared proposals on research infrastructure for biology and medical science that were included in the European Roadmap for Research Infrastructure (2006). Dr Barrington is a Trustee of the Irish Times and was awarded an honorary degree in laws by the National University of Ireland, Maynooth in May 2005.



BIOGRAPHIES

Mr John O'Brien

"Implementing the Cancer Control Strategy, challenges and opportunities"

John is Chief Executive of St. James's Hospital, the largest Academic Teaching Hospital in Ireland. He has extensive experience in Health and Hospital Management both Nationally and Internationally covering some 30 years. John has led and executed a large range of special interest initiatives in the Health Sector covering areas such as Information Systems, Strategy Planning, Commissioning of major health Enterprises, Corporate Governance and Executive systems design and large scale organisation reconfiguration and change. He has also participated as a member of a number of Ministerial/Department of Health & Children sponsored review groups including Steering Panels for the Value for Money Review of the Health System (Deloitte & Touche) and more recently the Audit of Structures and Functions in the Health System (Prospectus), which report formed the basis for the Major Reform Programme at present in implementation in the Irish Health System.

John holds graduate qualifications in Economics, Political Science and Health Management and a Masters degree in Public Administration. He also holds a Senior Lecturer position in Health Policy and Management with the University of Dublin, Trinity College. John is a Fellow of the Royal Academy of Medicine in Ireland and a member of the Irish Statistical and Social Enquiry Society.

In the area of quality, John has acted as Project Director of the National initiative established to develop an Accreditation Scheme for the Irish Health System. Up to 2004, he held the position of Transitional Executive Head of the Irish Health Services Accreditation Board (IHSAB), the Statutory Body established to, inter alia, administer this scheme. He was appointed Surveyor as part of the first wave initiative in this area in 2000 and has led surveys in Major Academic and large group Hospitals both in and outwith Ireland (including Canada, South East Asia, Australia etc.). He has also devised and overseen implementation of an extensive quality programme at St. James's Hospital in recent years.

With effect from January, 2006, he has been seconded to the Health Service Executive as a Special Advisor on Hospitals to the Chief Executive. Since his arrival he has taken up the role of National Director of the National Hospitals Office of the HSE on a temporary basis. This role embraces the entire Public Hospital System in Ireland (both direct and indirect) and a related budget of almost €4bn.

Dr David Lloyd

"Oncology exploration - panning for gold in bio-molecular space"

Dr David Lloyd is the Hitachi Senior Lecturer (in Advanced Computing) in the School of Biochemistry and Immunology, Trinity College Dublin, and is Trinity's Associate Dean of Research. He was awarded his BSc in Applied Chemistry and his PhD in Medicinal Organic Chemistry from Dublin City University. He spent several years as a post-doctoral researcher in the School of Pharmacy, TCD working on the computer-aided rational design of novel anti-estrogens for use as breast cancer chemotherapeutics. In 2001, Dr. Lloyd took up a post as Senior Scientist in the Applied Design group of De Novo Pharmaceuticals in Cambridge, UK, where he worked on many therapeutic projects using computational drug design strategies and techniques and headed the company's ligand-based design discovery program. He returned to Ireland and Trinity in 2004 to establish the Molecular Design Group - Ireland's largest and most successful rational drug discovery group. Funded by Science Foundation Ireland, Enterprise Ireland, the Health Research Board and Cancer Research Ireland, the group focuses on the integration of in silico and traditional wet lab drug discovery techniques, applying chemical biology and rational drug design strategies to a number of key therapeutic targets - with a major focus on oncology. Their core computational efforts are in the areas of virtual high-throughput screening and structure- and ligand-based design approaches, where their in silico predictions are validated using wet lab chemistries and in vitro assay.

BIOGRAPHIES

Dr Douglas Auld

“Quantitative High-Throughput Screening (qHTS): a valuable approach to identify Biological Activities in Large Chemical Libraries.”

Dr. Auld joined the NCGC in September of 2004 and has worked on establishing a center of scientific excellence that will serve the broader research community as a resource for assay optimization, high-throughput screening and chemical probe distribution. Dr. Auld is interested in applying existing technologies to new protein families as well developing new assay detection technologies to explore unconventional target classes. This includes the use of miniaturized assay formats to improve the quality and information content that is obtained in high-throughput screening campaigns of chemical libraries. With this in mind the NCGC has developed a concentration-response-based screening approach termed quantitative HTS (qHTS) where compounds are rapidly screened at 7 concentrations and now routinely applies this to both biochemical and cell-based assays on chemical libraries >100K in size. Prior to joining NCGC, Dr. Auld's received his Ph. D. in Chemistry from the University of North Carolina at Chapel Hill, NC. He was a Postdoctoral fellow within the Department of Biology at the Massachusetts Institute of Technology, Cambridge and Assistant Director of Drug Discovery at Pharmacoepia, Inc. Cranbury, NJ .

Dr Terry Rabbitts

“Macromolecular drug development and cancer experimental therapeutics”

ProfTerence Rabbitts is a molecular biologist working on genetic changes in human cancers. He worked in Cambridge, UK from 1973 in the MRC Laboratory of Molecular Biology (LMB) before becoming Director of the Leeds Institute for Molecular Medicine (LIMM) in 2006. He is currently Chairman of the OLK Medical Advisory Board. Professor Rabbitts's scientific work has included the invention of cDNA cloning, invention of chimaeric antibodies, determining the organization of the human immunoglobulin and T cell receptor gene loci and identification of primary oncogenic events in lymphoid cancers (such as LMO1, LMO2, HOX11, HOX11L2 chromosomal translocations) and mesenchymal cancers (such as the FUS-CHOP gene fusion). In recent years, he has developed mouse models that precisely recapitulate tumour-specific chromosomal translocations using new ES cell homologous recombination technologies. He also devised novel selection methods facilitating the development of intracellular antibody fragments as single immunoglobulin domains to target protein-protein interactions in cells. Dr. Rabbitts's interest in technology has facilitated his development of several widely used molecular biology techniques and he has recently developed a single molecule genome interrogation technique for examining the genomes of cancers that allows genome abnormalities (such as non-reciprocal translocation breakpoints) to be located and molecularly cloned. Professor Rabbitts has been awarded the Colworth Medal and the CIBA Prize. He is a Member of the European Molecular Biology Organization (EMBO), a Fellow of the Royal Society (FRS) and a Fellow of the Academy of Medical Sciences (FMedSci).

Dr Eva Szabo


“An apple a day... will chemoprevention keep the doctor away?”

Eva Szabo, MD, is Chief of the Lung and Upper Aerodigestive Cancer Research Group at the National Cancer Institute, NIH. She is a medical oncologist with a laboratory research background. Dr. Szabo's research has focused on thiazolidinediones in cancer prevention and treatment, identification of new agents for prevention of aerodigestive cancers, and on development of new clinical trials models for early phase testing of cancer preventive agents.

Prof Shane Allwright

“Influence of the Smoking ban on the health of Irish bar workers”

Shane Allwright is an associate professor of epidemiology in the Department of Public Health and Primary Care, Trinity College Dublin, and former member of the University Board. She is a member of the Board of the Office of Tobacco Control and chaired the Scientific Review Group commissioned by the Office of Tobacco Control / Health and Safety Authority on behalf of the Minister for Health and Children to report on the health effects of passive smoking in the workplace. This report (Report on the health effects of environmental tobacco smoke (ETS) in the workplace) was critical to the introduction of the Irish legislation banning workplace smoking. Her research interests include health effects of active and passive smoking and alcohol misuse; asthma and other respiratory diseases; and prisoner health. She was the lead investigator on a study of the impact of the ban on the respiratory health of bar workers (All Ireland Bar Study).


BIOGRAPHIES
Dr Ken Anderson
“Oncogenomics to Target Myeloma in its Bone Marrow Microenvironment”

Prof. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at John's Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. He has published more than 300 original articles, 200 chapters, and has edited multiple textbooks on multiple myeloma and on transfusion medicine. His numerous awards including the 2001 Charles C. Lund Award of the American Red Cross Blood Services, the 2003 Waldenstrom's award, the 2004 Johnson & Johnson Focused Giving Award for Setting New Directions in Science and Technology, the 2005 the Robert A. Kyle Lifetime Achievement Award, and the 2007 American Association for Cancer Research Joseph H. Burchenal Award for Clinical Research. Over the last two decades, he has focused his translational research studies on B cell malignancies, especially multiple myeloma. Highlights include: discovery of the first plasma cell reactive monoclonal antibodies; pioneering novel methods to improve safety and efficacy of autografting and allografting in myeloma; characterizing the signaling cascades whereby cytokines mediate myeloma cell growth, survival, and drug resistance; using oncogenomics and developing in vitro and in vivo models to both identify novel targets and validate therapies targeting the myeloma cell and its bone marrow milieu; translating these preclinical studies to the bedside in derived phase 1-3 clinical trials; and establishing a new treatment paradigm to overcome drug resistance and improve patient outcome in myeloma. He led both preclinical and clinical trials of the novel proteasome inhibitor Bortezomib, as well as thalidomide and its immunomodulatory derivative lenalidomide, culminating in the rapid FDA approval of these agents for treatment of myeloma.

FRIDAY 4th MAY 2007
Shelbourne Hotel
Prof Kevin Conlon
Prof Elaine Kay

Professor Elaine Kay is a consultant histopathologist in Beaumont Hospital, Dublin and Professor of Pathology at the Royal College of Surgeons in Ireland. She has served on the Board of the Faculty of Pathology since 1996 and as the National Specialty Director for Histopathology in the Republic of Ireland. She has an active research interest in solid organ malignancies with particular focus on markers with diagnostic utility and on markers of disease progression and response to treatment

BIOGRAPHIES

Dr Joe Harford

Dr. Joe Harford received a Ph.D. in Biochemistry from the University of Maryland Medical School and conducted basic research in molecular biology and cell biology at the National Institutes of Health from 1979 to 1993, rising to be Deputy Branch Chief of the Cell Biology and Metabolism Branch within NICHD. Dr. Harford has published over 100 scientific papers. In 1993, Dr. Harford became the chief scientist for RiboGene, Inc., a then-privately-held biotechnology company. There, he managed four drug discovery programs in infectious diseases and cancer that collectively received more NIH SBIR grant funding in FY1996 than any other drug discovery company in the Nation. He participated in raising venture capital and in negotiations that culminated in an alliance with a major pharmaceutical company and eventually an initial public offering for RiboGene. In 1996, Dr. Harford returned to the NIH where he served as Associate Director of the NCI and Chief of Staff of the Office of the Director, a diverse group of offices with responsibilities that include preparation of the NCI budget, press relations, and interactions with the U.S. Congress, patient advocacy groups and professional organizations. Currently, Dr. Harford is the Chair of NCI's Technology Review Group, responsible for review of employee inventions and recommendations for actions taken regarding patent strategy for technology transfer activities. In July 2002, Dr. Harford was named Director of the Office of International Affairs of the National Cancer Institute. In this capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreign cancer research institutions and other foreign entities. His office also tracks all funding going to foreign investigators through NCI grants and contracts as well as other forms of international collaboration. Dr. Harford serves as the Chair of the Strategic Advisory Group of the Ireland-Northern Ireland-NCI Cancer Consortium and as NCI liaison to the Middle East Cancer Consortium, the US-Japan Cooperative Cancer Research Program, the African Organization for Research and Training in Cancer, the American-Russian Cancer Alliance, and the International Network for Cancer Treatment and Research. Dr. Harford also represents the United States to the Governing Council of the WHO's International Agency for Research on Cancer. In July 2006, Dr. Harford was named as Strategic Leader for Knowledge Transfer by the International Union Against Cancer (UICC) and in this capacity serves on the UICC Strategic Coordinating Committee.

Des Fitzgerald

Professor Desmond Fitzgerald is a UCD medical graduate who trained in Cardiology and Clinical Pharmacology at Vanderbilt University. Prior to his current appointment as Vice-President for Research in UCD, he was Professor of Clinical Pharmacology at RCSI, where over 10 years he built a department of 120 teaching and research staff with divisions that included cardiovascular pharmacology, mass spectrometry, proteomics, bioinformatics and neuroscience. In his previous appointment, Professor Fitzgerald was also Director of the Institute of Biopharmaceutical Sciences at RCSI and led their HEA PRTL programme, which was awarded €65 million over three successive cycles. The team also attracted more than €17 million in funding from Science Foundation Ireland. In addition to his academic post, he was a Consultant in Clinical Pharmacology at Beaumont Hospital and a Consultant in Cardiology at the National Maternity Hospital. Professor Fitzgerald has published more than 140 papers on cardiovascular pharmacology and inflammation and currently leads a Molecular Medicine group in the Conway Institute. Professor Fitzgerald is on the Editorial Board of several journals including *Circulation* and *Thrombosis & Haemostasis*, and was formerly Chairman of the Working Group on Platelets and Thrombosis at the European Society of Cardiology.

Mr Peter Finnegan

Peter Finnegan is presently Director of Innovation and International Relations with Dublin City Council. In his previous positions within the Council as Director of the Development Board and Strategic Initiatives he worked with the Health Authorities on a community based cancer awareness programme called "Your Health is your wealth." Peter has an MA in Adult Learning and an MBA. He previously worked in FAS and had responsibility for the development of community based learning and development. He is committed to the concept that solutions to challenges facing society such as those of preventative health approaches lie in the development of awareness and mobilisation of networks within communities.



BIOGRAPHIES

Prof Patrick Cunningham

Patrick Cunningham is Chief Scientific Adviser to the Irish Government and Professor of Animal Genetics in Trinity College, University of Dublin. He was formerly Deputy Director (Research) in the Irish National Agriculture and Food Research Institute (1980 - 1988), visiting Professor at the Economic Development Institute, World Bank (1988) and Director of the Animal Production and Health Division, Food & Agriculture Organisation of the UN, Rome (1990 - 93). He has published extensively on the genetics of domesticated animals. He is co-founder and Chairman of the biotechnology company IdentiGEN. He has been President of the European and World Associations of Animal Production, and served on the European Life Sciences Group which advised Commissioner Busquin.

Dr John Kennedy

Dr. Kennedy holds the position as Consultant Medical Oncologist at St James's Hospital and St. Lukes Hospital and Director of the Cancer Clinical Trials Consortium at St James's Hospital. Dr. Kennedy qualified from the University of Dublin, Trinity College where he was awarded a first class degree and won the university Gold Medal in 1983. His training took him from Ireland to the United States where he began a Clinical Fellowship in Oncology at the renowned Johns Hopkins University in Baltimore in 1987 and rose to the position of Associate Professor of Oncology before returning to Ireland in 1998. He is the Vice Chairman of the Irish Clinical Oncology Research Group (ICORG), immediate past Chairman of the Irish Society for Medical Oncology, and Chairman of the Medical Committee of the Irish Cancer Society. His major research interest is in breast cancer.

Prof Dermot Kelleher

"Oesophageal cancer; molecular insights into the inflammation - cancer sequence"

Prof Dermot Kelleher graduated with First Class Honours in Medicine from TCD in 1978 and completed specialist training in Gastroenterology in Dublin. He subsequently received a Fogarty Scholarship for a research fellowship at University of California San Diego. In 1989 he was appointed as a Wellcome Senior Fellow in Clinical Science at Trinity College Dublin and was subsequently appointed as Professor of Clinical Medicine in 2001. Professor Kelleher's research has focussed on the cell biology of immune responses both in terms of basic lymphocyte function and in relationship to mucosal immunology. He is the author of over approximately 150 publications including papers in journals such as Nature Immunology, Journal of Experimental Medicine, Gastroenterology, Hepatology, Journal of Biological Chemistry and Journal of Immunology. He is also the author of 12 patents. Prof Kelleher in collaboration with Prof Hugh Brady at UCD has obtained collaborative grant funding to establish the Dublin Molecular Medicine Centre a joint venture between the three major medical schools in Dublin which provides a physical infrastructure for major developments in medical biotechnology in Ireland. Prof Kelleher is the inaugural director of the Institute of Molecular Medicine, a TCD facility at St James's Hospital. He is Director of TCD HRB 4 year PhD Programme in Molecular Medicine. Prof Kelleher is Principal Investigator of a €20m Wellcome Trust Clinical Research Infrastructure Grant awarded in 2006. He is a member of the Board of the Health Research Board Ireland, the European Medical Research Council and the Wellcome Trust Clinical Interest Group. Professor Kelleher is a co-founder of two nanotechnology companies, Deerac Fluidics and Cellix, utilising nanotechnology for the study of human disease.

Prof Phil Quirke

"Modern pathology and colorectal cancer"

Professor of Pathology, University of Leeds
 Head of Pathology & Tumour Biology, Leeds Institute of Molecular Medicine
 Honorary Consultant Pathologist, Leeds Teaching Hospitals NHS Trust

BIOGRAPHIES

Prof Marc Peeters

“Targeted therapies show great promise against colorectal cancer”

Dr Marc Peeters is a staff member in the Department of Gastroenterology and Coordinator of the Oncology Health Programme at the University Hospital Gent, Belgium. He is assistant Professor of Medicine at the State University of Ghent. In 1996, he attained his PhD in Medical Sciences having first completed his medical degree at the Katholieke Universiteit Leuven, Belgium. He started as a staff member at the University of Leuven and since 2000 is working in Ghent. He is coordinator of the multidisciplinary Digestive Oncology workgroup. Research in this field consists of identification of predictors for response. As both a principal and co-investigator, Dr Peeters is involved with early phase clinical trials in digestive oncology. Dr Peeters published several peer reviewed papers as a first author or co-author in the field of digestive oncology and IBD. He is a member of several scientific societies, including the European Society of Medical Oncology (ESMO), the Belgian Society of Medical Oncology (BSMO), the Belgian Group of Digestive Oncology (BGDO) and the gastrointestinal group of the European Organisation for Research and Treatment of Cancer (EORTC). He is also President of the Flemish Society of Gastroenterology.

Dr Anna Barker

“The Nanotechnology Alliance against Cancer (Exact Title to be confirmed)”

Dr. Barker serves as the Deputy Director of the National Cancer Institute (NCI) and as the NCI's Deputy Director for Advanced Technologies and Strategic Partnerships. In this role she is a member of the Executive Committee and leads and/or participates in all aspects of strategic planning, decision making and program implementation to achieve the NCI's mission. Since joining the NCI in 2002, she has also led the planning, development and implementation of a number of strategic scientific and technology initiatives and partnerships. Dr. Barker completed her Ph.D. at the Ohio State University; where she trained in immunology and conducted research on the differentiation of leukemic T-cells and specific immunotherapy of hematologic malignancies. Her research interests have been primarily in drug discovery and development and immunotherapy, with a focus on reactive oxygen species (ROS) signaling and biology relative to inflammatory diseases and cancer treatment and prevention.

During her tenure at the NCI, Dr. Barker has led and overseen the planning and implementation for strategic national initiatives in several key areas of science and technology. The following represent a few key examples:

- Bioinformatics - The Cancer Bioinformatics Grid (caBIG), which has as its goal ultimately connecting the basic, translational and clinical cancer research enterprise was initiated as a pilot program in 2003;
- Biomarkers – Launched in 2006, the NCI's Clinical Proteomics Teams Initiative seeks to standardize and deploy the technology platforms, reagents and protocols needed to enable cancer investigators to systematically and reproducibly define human cancer protein biomarkers;
- Genomics – Launched in late 2005, The Cancer Genome Atlas (TCGA) Pilot Program is a large scale three-year pilot program being undertaken jointly by NCI and the National Human Genome Research Institute (NHGRI) to identify all significant genetic changes in cancer;
- Biospecimens – Initiated in 2002, the analysis of NCI's biospecimen resources led to the development of 1st generation guidelines for NCI-funded biorepositories (recently published in the Federal Register) to ensure that future biospecimens are of the highest quality and adhere to strict bioethical standards to optimally support post-genomics cancer research;
- Nanotechnology for Oncology – Launched in 2005 after extensive planning, the Nanotechnology Alliance for Cancer, represents a major NCI initiative in this emerging field. The Alliance seeks to ensure that advances in medical/cancer nanotechnology are specifically developed and ultimately applied to address key issues and barriers in all areas of cancer research; especially biosensors for early detection and drug development and delivery.



BIOGRAPHIES

William Kaelin

“Intelligent Selection of Drug Targets Based on Cancer Genetics”

William G. Kaelin Jr., M.D., is a Professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women's Hospital, Harvard Medical School. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in internal medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in medical oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in the laboratory of David Livingston, during which time he was a McDonnell Scholar.

Dr. Kaelin is a member of the American Society of Clinical Investigation and the American College of Physicians. He recently served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center and the Richard and Hinda Rosenthal Prize from the AACR.

A Howard Hughes Medical Investigator since 1998, Dr. Kaelin's research seeks to understand how, mechanistically, mutations affecting tumor-suppressor genes cause cancer. His laboratory is currently focused on studies of the VHL, RB-1, and p53 tumor suppressor genes. His long-term goal is to lay the foundation for new anti-cancer therapies based on the biochemical functions of such proteins. His work on the VHL protein led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as myocardial infarction and stroke.

John Tierney

“The role for local government in Cancer Healthcare”

John Tierney, the Dublin City Manager, began his local government career with North Tipperary County Council in 1977. He has worked with eight different local authorities prior to joining Dublin City. John holds a BA and MA in Public Management from the Institute of Public Administration. He is Chair of the Steering Group which monitors the Strategic Planning Guidelines for the Greater Dublin Area. He is a member of the Management Committee of the National, Economic and Social Forum, he is a Director of the Affordable Homes Partnership Board and he also was Chairman of the National Postcode Project Board.

Prof Dennis McCance

“Human Papillomaviruses (HPV) and Cancer; the role of viral proteins in targeting epithelial differentiation”

Prof McCance received his Ph.D. University of Birmingham, England and was Senior Lecturer in Guy's Hospital Medical School, London before he was appointed Professor, Microbiology and Immunology and of Oncology, Head of the Virology Unit, Dept. of Microbiology and Immunology, University of Rochester, NY in 2005. He has recently been appointed as Professor of Cancer Research and Cell Biology, Queen's University, Belfast. He received the Howard Hughes Fellowship, University of Chicago in 1987 and the American Cancer Traveling Fellowship (for sabbatical leave at the University of Cambridge, UK, 1996-1997). In 1997 he received the Dean's Senior Teaching Award, University of Rochester NY. He has published widely in international journals and has a particular interest in the role of viruses in cancer.

Dr Stephen Chanock

“Genetic susceptibility to prostate cancer – the Devil's in the DNA”

Dr. Chanock received his M.D. from Harvard Medical School and completed training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute, Boston. Afterwards, he joined the NCI where he has an interest in the molecular, cellular, and clinical problems of infectious complications in patients with cancer and HIV infection.

BIOGRAPHIES

Prof Peter Parker

"Insights into targeting the PI3Kinase pathway"

Peter Parker was trained as an undergraduate in Biochemistry (BA) at Oxford and then as a post-graduate under Professor Sir Philip Randle in Clinical Biochemistry (D.Phil) at Oxford. He was subsequently awarded an MRC Post-Doctoral Fellowship with Professor Sir Philip Cohen in Dundee. Following this Peter took on an ICRF Fellowship to work with Professor Mike Waterfield in London. Peter has run an independent research group since 1986. Peter has a long-standing interest in signal transduction, with a particular expertise in kinases and cancer. This covers current research in biochemical, cell biological and genetic aspects of specific kinases, as well as active engagement in drug discovery programmes. Peter has published over 250 primary research articles and reviews in this area and has been recognised by the research community for these contributions. Peter was elected to the European Molecular Biology Organisation in 1995, to the Academy of Medical Sciences in 2000, he was awarded the Morton Prize in 2004 and elected to the Royal Society in 2006.


Prof Peter Daly

"A story of Tigers and Crabs; cancer care in a changing Ireland"

Dr Peter A. Daly is a Consultant Medical Oncologist at St James's Hospital, Dublin and Associate Professor of Medicine in the Department of Clinical Medicine of Trinity College, Dublin. He has been involved in clinical cancer care for 30 years. He graduated from University College Dublin in 1971 and undertook general medical training at the Mater Misericordiae University Hospital, St James's Hospital and the Federated Dublin Voluntary Hospitals, notably Sir Patrick Dun's. He returned to Ireland in 1979 and has worked as a cancer physician at Mercer's Hospital until its closure in 1983 and at St. James's from 1979 to the present. As one of the earliest consultants in the field of cancer medicine, he has been to the forefront in developing Medical Oncology in Ireland and was a member of the 1st and 2nd Fora on Development of Cancer Services in Ireland. He served on the Steering Committee which developed BreastCheck, the National Breast Cancer Screening Programme as well as many other National and European Committees. He is a founder member and was the first secretary of the Irish Society of Medical Oncology and subsequently its president. He was a founding member of ICORG, the Irish Clinical Oncology Research Group. He served on the first committee of the NCI / Ireland / Northern Ireland Cancer Consortium and remains committed to the development of cancer services as well as training and education opportunities on the island of Ireland. He has just completed a three-year period as National Specialty Director for Medical Oncology for the Irish Committee on Higher Medical Training. Research interests are inherited predisposition to cancer, malignant lymphomas and supportive care. Dr Daly has published extensively in these areas and on issues in general medical oncology practice. He is a member of the Faculty in Cancer Genetics of ESMO. Dr Daly has been married for 34 years to Mary. They have four children and one grandchild.



BIOGRAPHIES



SPONSORS

We would like acknowledge and thank the following sponsors for their kind contribution to the Cancer 2007 Conference.

Gold Sponsors

Irish Cancer Society

Health Research Board

NCI

Silver Sponsors

Baxter

Novartis

Roche

Bronze

Astra Zeneca

Amgen

Bristol Myer Squibb

Marie Keating Foundation

National Cancer Screening Service

Pfizer

Schering

Varian

Other Contributors

Bioscience

Department of Health and Children

Department of Health, Social Services and Public Safety

Slidepath



SPONSORS

Gold Sponsors



Silver Sponsors



Bronze



Other Contributors





SPONSORS

Gold Sponsors



Silver Sponsors



Bronze



Other Contributors



SPONSORS

The Irish Cancer Society, is the national charity dedicated to eliminating cancer and improving the lives of those living with cancer. Its main areas of focus are the delivery of health promotion and cancer prevention campaigns and programmes, the delivery of free nationwide patient care services for people with cancer and their families and the funding of pre-clinical and clinical cancer research.

The Society is the largest single voluntary supporter of cancer research in Ireland and funds research to the tune of approximately €2.6 million per year in Irish hospitals and universities. All cancer research activities are managed through Cancer Research Ireland (CRI), the research division of the Irish Cancer Society.

The Society, founded in 1963, is financed entirely by voluntary contributions from the public and receives no government funding for the development and delivery of its services.

The Health Research Board (HRB) is the lead agency supporting and funding health research in Ireland. We provide funding, maintain health information systems and conduct research linked to national health priorities. Our aim is to improve people's health, build health research capacity, underpin developments in service delivery and make a significant contribution to Ireland's knowledge economy.

Our current investment to underpin research that will help tackle Cancer is €25.9 million. We work closely with the Ireland – Northern Ireland – National Cancer Institute Cancer Consortium which aims to reduce the incidence and mortality of cancer on the island of Ireland.

The National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health

and is the U.S. Government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. Specifically, the NCI supports and coordinates research projects conducted by universities, hospitals, research foundations, and businesses throughout the U.S. and abroad through research grants and cooperative agreements; conducts research in its own laboratories and clinics; supports education and training in fundamental sciences and clinical disciplines for participation in basic and clinical research programs and treatment programs relating to cancer through career awards, training grants, and fellowships; supports research projects in cancer control and a national network of cancer centers; collaborates with voluntary organizations and other national and foreign institutions engaged in cancer research and training activities; encourages and coordinates cancer research by industrial concerns where such concerns evidence a particular capability for programmatic research; collects and disseminates information on cancer; and supports construction of laboratories, clinics, and related facilities necessary for cancer research through the award of construction grants.

Baxter Healthcare is a global healthcare company, with a team of 45,000 people working in 250 facilities worldwide. Our focus is on advancing the best standard in healthcare.

Baxter has been working in partnership with healthcare professionals and hospitals in Ireland for over 30 years. We are committed to helping these professionals to meet the increasing challenges and demands of today's healthcare environment. As part of this commitment, Baxter is driving homecare in Ireland in a variety of therapeutic areas including oncology, haematology, cystic fibrosis, nephrology, rheumatology and nutrition. Our mission is to apply our expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

Novartis Oncology

At Novartis Oncology, our primary goal is to research and develop new and more effective ways to treat cancer - in essence, to bring our vision of research to life. Novartis Oncology is exploring various novel compounds in all phases of development, and is pioneering signal transduction inhibition, antiangiogenesis, novel cytotoxics, iron chelation, and other exciting areas that are likely to change the way cancer is treated in the future.

Our mission is to become the world's premier oncology company by consistently discovering, developing, and producing broadly available novel therapies that improve and extend the lives of patients with cancer. Through our rich, broad, and deep pipeline, we are poised to shape cancer research and treatment tomorrow.

Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of



SPONSORS

products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.

The Marie Keating Foundation

"Following their mother Marie's death in 1998 each member of the Keating family promised that they would do everything they could to bring an end to breast cancer. They committed to provide all women and their families with the necessary information to prevent cancer or detect it at its earliest stages. Their collective aim was to "enlighten not frighten". The Marie Keating Foundation is the realisation of a family's dedication – it is a promise to themselves in action. Through three mobile information units the Foundation's dedicated nurses have enlightened almost 60,000 people of the causes and risk factors of breast and other cancers. "Men Keeping Fit" is now a successful annual campaign and has significantly raised awareness among men of testicular and prostate cancer.

The Foundation finances other areas of need in cancer care. Monies raised help to refurbish hospital oncology waiting rooms in making them more comfort-

able for patients. A comfort fund for those in financial difficulty as a result of their illness provides immediate assistance, when required. The Foundation is committed to raising awareness among young people in schools of cancer and its prevention. The Foundation provides its services free of charge."

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of \$26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

The National Cancer Screening Service was established on January 1st 2007, by the Minister for Health & Children, Ms

Mary Harney.

The National Cancer Screening Service has responsibility for BreastCheck, the National Breast Screening Programme, for the Irish Cervical Screening Programme (ICSP) and for other potential cancer screening programmes.

BreastCheck is preparing for national roll-out of the programme. Screening Units are under construction in the South (Cork) and the West (Galway), a recruitment process is underway for staff, and equipment and mobile screening units are in the process of being procured. The Screening Units will be completed in late Autumn 2007 and following a three-week period for commissioning will be ready to invite women for screening.

Until 1st January 2007, the existing phase 1 of the Irish Cervical Screening Programme was based in the mid-Western area under the governance of the HSE. The National Cancer Screening Service has been charged with rolling out the programme nationally.

Mr Tony O'Brien is the Chief Executive Officer of the National Cancer Screening Service and Dr Sheelah Ryan is the Chairperson of the new National Cancer Screening Service Board.

Pfizer Oncology is committed to advancing the scientific understanding of cancer and to bringing new medicines to millions of cancer patients. Oncology is a research priority for Pfizer, with over 12 percent of the company's research and development investment devoted to discovering and developing innovative therapies for treating breast, colorectal, renal cell carcinoma, gastrointestinal stromal tumour and other cancers

SPONSORS

Bayer Schering Pharma

The recent information of Bayer Schering Pharma AG has brought together two companies with a strong history in oncological and onco-haematological research and a complementary portfolio of products, to create an exciting new force in clinical oncology. With six major products currently in clinical use and a rich pipeline of new agents in development, Bayer Schering Pharma aspire to become one of the ten top oncology companies within the next decade. To achieve this we are committed to developing our rich portfolio by working closely with oncologists who share our long-term commitment to improving the lives of patients with cancer and through the development of robust clinical data .

Varian Medical Systems is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X-ray tubes and flat-panel digital sub systems for imaging in medical, scientific, and industrial applications. For more information, visit www.varian.com.

Bristol-Myers Squibb

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Bio-Sciences Limited is a leading distributor of Laboratory equipment, and Cell Culture and Molecular Biology consumables in Ireland. Bio-Sciences Limited, is a wholly Irish owned business which was founded in August 1992 by Gerry Byrne and Brian Fitzpatrick. We are pleased to be associated with the 5th International Cancer Conference and look forward to seeing you

at our trade stand. We would like to welcome you to visit us to view some exciting new products from Invitrogen including the Iblot and Qubit. We will also be featuring our new Real Time Quantitative PCR Machine from Corbett.

The Department of Health, Social Services and Public Safety was established by the Departments (NI) Order 1999. The Department administers the business of:

- Health and Personal Social Services, which includes policy and legislation for hospitals, family practitioner services, community health and personal social services;
- Public Health, which covers responsibility for policy and legislation to promote and protect the health and well-being of the population of Northern Ireland; and
- Public Safety, which encompasses responsibility for the policy and legislation for the Fire Authority, food safety and emergency planning.

Strategic Direction
The Department's mission is to improve the health and social well-being of the people of Northern Ireland. It endeavors to do so by ensuring the provision of appropriate health and social care services, both in clinical settings, such as hospitals and GPs'surgeries, and in the community, through nursing, social work and other professional services. It also supports programmes of health promotion and education to encourage the community to adopt activities, behaviours and attitudes which will lead to better health and well-being.

Slidepath is a rapidly expanding Irish informatics company, whose core focus is the development of knowledge and image management solutions

that accelerate life-sciences research and streamline data consolidation and access. SlidePath have significant experience and expertise in the design and implementation of scientific information management solutions for use in medical and life-science contexts, also the generation, storage, review and analysis of digital microscopy images. SlidePath also have significant knowledge in the development of advanced biostatistics and bio-data analysis solutions.

Slidepath have considerable experience in the development of large digital archives of digital pathology slides that can be used for undergraduate and postgraduate medical training. Working extensively with national and international partners SlidePath have developed sophisticated, on-line, information management resources for life-sciences image and data management. The solutions allow distributed researchers to share information and interact using online resources that are secure, flexible and highly extensible.

Slidepath have developed specialist solutions for specific life sciences research application and medical domains. Field of expertise include; high-throughput Tissue Microarray analysis solutions that enable rapid reading of large numbers of array spots with real-time integration of observations into the clinical dataset facilitating rapid biomarker expression profiling, custom tools for the creation of reports and notifications for use in preparing for and attending multidisciplinary meeting, and the design of bio-banking and sample distribution and tracking solutions.